Roche AG, of Basel, Switzerland, said its unit Genentech received word that the FDA approved a supplemental biologics license application for Gazyva (obinutuzumab) in combination with chlorambucil chemotherapy in people with previously untreated chronic lymphocytic leukemia (CLL).